Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_95577

CRISPR cancer therapy trial gets go-ahead in US

27 June 2016
Appeared in BioNews 857

The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board.

The National Institute of Health's (NIH) recombinant DNA research advisory committee (RAC) last week approved a proposal for an early-stage trial that will test the safety of CRISPR to treat patients with three types of cancer: myeloma, melanoma and sarcoma.

The trial, proposed by scientists at the University of Pennsylvania (see BioNews 856), involves editing genes in T cells – a type of white blood cell. It will involve around 15 cancer patients and will be carried out at three centres: the University of Pennsylvania, MD Anderson Cancer Center in Houston, and the University of California at San Francisco.

The researchers will remove T cells from the patients and edit them in three ways – using CRISPR – before injecting the cells back into the patient. The first CRISPR edit will insert a protein engineered to detect cancer cells and instruct the T cells to target them, and the second will remove a protein that could interfere with this process. The final edit will prevent the cancer cells from disabling the T cells, by removing the gene that identifies the T cells as immune cells.

During the committee meeting, one of the concerns raised was a potential conflict of interest as one of the researchers holds patents on T-cell technologies and could stand to benefit if the trial is successful. Another concern was the history of gene technologies at the University of Pennsylvania – in 1999, an early gene-therapy trial by researchers at the university resulted in the death of 18-year-old Jesse Gelsinger, and a subsequent investigation found serious problems with the study, including unreported data on the therapy's adverse effects in animals.

'Any first use in humans we have to be extraordinarily careful,' Professor Laurie Zoloth, a bioethicist at Northwestern University in Evanston, Illinois, told Nature News. However, the decision by the committee was unanimous, with only one member abstaining.

Following the approval from the NIH, the research team will now have to seek approval from the US Food and Drug Administration – which regulates clinical trials in the US – as well as review boards at their own institutions, in order to carry out the trial. However, Professor Carl June, an immunologist at the University of Pennsylvania who is a science adviser on the project, told Nature News that the trial could begin by the end of the year.

The research is being funded through a charitable foundation set up in April by tech billionaire Sean Parker to give $250 million in funding to six cancer centres.

The NIH approval could see more trials involving CRISPR being proposed, including one from Editas Medicine in Massachusetts, which is planning a clinical trial using the technology to treat a rare form of blindness (see BioNews 828).

SOURCES & REFERENCES
Federal panel approves first test of CRISPR editing in humans
Washington Post |  21 June 2016
First CRISPR clinical trial gets green light from US panel
Nature News |  22 June 2016
Money Behind First CRISPR Test? It’s from Internet Billionaire Sean Parker
MIT Technology Review |  20 June 2016
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 April 2018 - by Shaoni Bhattacharya 
Europe's first clinical trial to use genome editing in humans has received approval to start later this year...
29 January 2018 - by Hannah Tippett Simpson 
The US National Institutes of Health (NIH) has announced its intention to grant US$190 million for genome editing research...
30 May 2017 - by Annabel Slater 
US scientists have delayed cancer cell growth by using genome editing to remove a protein...
8 May 2017 - by Sarah Pritchard 
Aggressive human prostate and liver tumours have been shrunk in mice by targeting a ‘fused’ gene mutation using CRISPR/Cas9...
21 November 2016 - by Anneesa Amjad 
Chinese scientists have injected CRISPR/Cas9 gene-edited cells into a human for the first time...
14 November 2016 - by Sarah Gregory 
Researchers have had further success using the CRISPR/Cas9 genome-editing technique to repair the mutation that causes sickle-cell anaemia...
17 October 2016 - by Sarah Gregory 
Researchers have used the CRISPR/Cas9 genome-editing technique to correct the mutation that causes sickle-cell anaemia...
3 October 2016 - by Helen Robertson 
Two teams of researchers have used CRISPR genome editing technology to identify 'non-coding' regions of the genome for the first time...
12 September 2016 - by Dr Özge Özkaya 
Scientists from China have managed to shrink the size of tumours in mice using CRISPR/Cas9 genome-editing technology...
25 July 2016 - by Rachel Siden 
Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans – on patients with lung cancer – this August...
20 June 2016 - by Rachel Reeves 
A US federal safety board is set to review an application for the first in-human use of CRISPR/Cas9 genome-editing technology to treat cancer...
6 June 2016 - by Ayala Ochert and Amina Yonis 
The team that developed the CRISPR/Cas9 DNA-editing technique have now developed a new system that could allow RNA editing...
16 May 2016 - by Sarah Gregory 
Researchers have developed a quick and cheap 'paper-based' test that uses CRISPR to detect the Zika virus...
25 April 2016 - by Dr Özge Özkaya 
Scientists have fine tuned the genome-editing tool CRISPR so that it can now edit a single 'letter' of DNA...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.